secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001213900-24-000247
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma FY2023 net loss $32.5M; Mino-Lok Phase 3 enrollment done, topline Q2 2024
--------------------------------------------------------------------------------

- Net loss $32.5M ($0.22/share) for FY ended Sep 30, 2023; cash $26.5M, runway through Aug 2024.
- Mino-Lok Phase 3 completed (241 patients, 109 events); topline results expected Q2 2024.
- LYMPHIR BLA resubmission on track for early 2024 after July 2023 CRL; PDUFA later in 2024.
- Halo-Lido Phase 2b completed; end-of-Phase 2 meeting with FDA planned early 2024.
- Oncology subsidiary to merge with TenX Keane Acquisition (TENKU) to form publicly listed Citius Oncology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024000247/0001213900-24-000247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024000247/ea190916-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-000247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer